Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.

A. J. Ferreri, G. P. Dognini, C. Verona, C. Patriarca, C. Doglioni, M. Ponzoni

Research output: Contribution to journalArticlepeer-review

Abstract

We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure. The loss of CD20 expression in B-cell lymphomas relapsing after rituximab is a well-known phenomenon, but its actual impact in DLBCL is difficult to estimate. This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas. Accordingly, every relapse, whenever possible, should be histologically assessed with diagnostic and immunophenotyping purposes.

Original languageEnglish
JournalHaematologica
Volume92
Issue number1
DOIs
Publication statusPublished - Jan 2007

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.'. Together they form a unique fingerprint.

Cite this